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ABSTRACT   
OBJECTIVE: The objective of this selective EBM review is to determine whether or not oral 
finasteride is effective in reversing hair loss in men with androgenetic alopecia.   
 
STUDY DESIGN: Review of two double blind, randomized controlled trials (RCTs), and one 
randomized open-label study published between 2009 and 2013, all in English language. The 
articles compared oral finasteride to a placebo, topical finasteride, and Serenoa repens, 
respectively.  
DATA SOURCES: The two double-blind, randomized controlled trials (RCTs), and one 
randomized open-label study were found using PubMed. All articles were published in peer- 
reviewed journals and selected based on correlation to topic choice, date of publication, and 
evaluating POEMs. 
OUTCOMES MEASURED: Patient reported satisfaction with therapy, change in staging from 
baseline as measured by the Hamilton and the Hamilton-Norwood Classification Scale for 
androgenetic alopecia, and change in mean size of alopecia from baseline (cm).  
RESULTS: The three studies used in this review demonstrated inconsistent data on the 
effectiveness of oral finasteride for reversing hair loss in men with androgenetic alopecia. Rossi 
et al. demonstrated a statistically significant change in hair growth reversal in men taking oral 
finasteride when compared to Serenoa repens (P=0.013). Gubelin Harcha et al found statistically 
significant data that men treated with oral finasteride perceived they had increase in hair growth 
at the end of the trial when compared to the placebo.  However, Gubelin Harcha et al found 
statistically insignificant data to support that men were overall satisfied with hair growth at the 
end of the trial (P=0.084).  Hajheydari et al. demonstrated oral finasteride was statistically 
insignificant in reversing hair loss in men when compared to topical finasteride. 
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INTRODUCTION  
 Male androgenetic alopecia, also known as male pattern balding, is the most common 
cause of hair loss in men.1  Androgenetic alopecia is a condition that affects the hair follicles, 
resulting in a pattern of hair thinning and hair loss.  It is characterized by a progressive 
transformation of terminal hair into villus hair. 1,2  The age of onset for androgenetic alopecia in 
men is generally in the late teens and early twenties but varies, and prevalence has been found to 
increase with age. Approximately 80% of men above the age of 60 are affected, and roughly 
16% of men ages 18-29 and 53% of men ages 40-49 exhibit moderate to extensive androgenetic 
alopecia. 1,3,4  The disorder is around 4 times more common in Caucasian men than in African 
American men.  When compared to Caucasian men, androgenetic alopecia affected men of 
Chinese origin less frequently and at a later age.  In men of Japanese origin, the age of onset of 
androgenetic alopecia was found to be approximately 10 years after that of Caucasian men.4 
Male pattern balding is believed to have both an endocrine and genetic component.  The 
main hormone that is linked to androgenetic alopecia is testosterone, specifically 
dihydrotestosterone (DHT), and active metabolite of testosterone. 1-6  DHT is converted from 
testosterone by the enzyme 5-alpha-reductse.1-6  There are two isoforms of 5-alpha-reductase that 
are able to convert testosterone to DHT, Type 1 and Type 2.2,4-6 Type 1 is mostly found in the 
hair follicles and the sebaceous glands of the skin, whereas Type 2 is generally found in the inner 
root sheath of hair follicles and the male genitalia and prostate.4,6 Higher concentrations of 5-
alpha-reductase in the body are linked with androgenetic alopecia in men.2 
 Evidence suggests that androgenetic alopecia also has a familial component and 
polygenic inheritance.1,2   Twin studies show an 80% predisposition to hair loss. Polygenic 
inheritance is also supported by evidence that there is an increased risk for androgenetic alopecia 
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in families with increased number of affected individuals2. This is thought to be due to an 
abnormality of the androgen-receptor gene on the X-chromosome, which would lead to maternal 
inheritance of androgenetic alopecia, as well as a mutated locus on chromosome 3.2  
 Current FDA approved medications for hair restoration due to androgenetic alopecia 
include topical minoxidil (Rogaine) and oral finasteride.1,2,6  Other off-label medications used to 
help reverse hair loss are dutasteride, latanoprast, and topical finasteride.2,5  Hair transplant 
surgery is also an effective therapeutic option for long-term treatment of androgenetic alopecia. 
1,2,4  It is estimated that millions of dollars are spent annually on products to help reverse hair 
loss.4  
 
Objective 
The objective of this selective EBM review is to determine whether or not oral finasteride is 
effective in reversing hair loss in men with androgenetic alopecia (male pattern baldness).   
 
Method 
Two randomized control studies and one randomized open label study were used in this 
review.  These studies consisted of men ages 18 and older diagnosed with androgenetic alopecia. 
Gubelin Harcha et al. compared the effectiveness of 4 control groups receiving either 0.02mg, 
0.1 or 0.5mg/day of dutasteride or a placebo, and an experimental group receiving 1mg/day of 
finasteride.  Each of the 5 groups received their randomly assigned medication daily for a total of 
24 weeks.  At the 12th and 24th week of the experiment, a 3-question Hair Growth Index (HGI) 
questionnaire was given to each participant to assess their subjective perception of their amount 
of hair. The HGI included a 7-point scale that ranged from “much less hair” to “much more 
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hair”.  Each participant was also given a 5-question Hair Growth Satisfaction Scale (HGSS) 
which was administered at 12 and 24 weeks to assess the participants’ satisfaction.  The HGSS 
also had a 7-point scale that ranged from “very dissatisfied” to “very satisfied”.  Gubelin Harcha 
et al. also used the Hamilton-Norwood Classification Scale to assess each participant’s change in 
stage of androgenetic alopecia at the end of the 24-week trial.  The change in each participant’s 
staging was used to assess their therapeutic response. The secondary outcomes measured in this 
study were hair growth, change in terminal hair count, and an investigator photographic 
assessment questionnaire; however, these outcomes are not addressed in this paper.6 
Hajheydari et al. conducted a double-blind randomized clinical trial to compare the 
effectiveness of a control group of topical finasteride gel with an experimental group receiving 1 
mg of finasteride per day by mouth.  Effectiveness of treatment was evaluated by comparing 
change in the size of alopecia in centimeters for both groups at the end of the 6-month trial and 
the overall effectiveness of each therapy measured after each month.  Secondary outcomes 
measured in this study were hair count and change in number of terminal hairs at the end of the 
study; however; these secondary outcomes are not considered POEMS and will not be addressed 
in this paper.5 
Rossi et al. conducted a randomized open label study comparing a control group of 
Serenoa repens, a plant also known as saw palmetto, with the experimental group of oral 
finasteride for the treatment of male androgenetic alopecia.  This experiment measured the 
outcomes of each therapy for 24 months.  Outcomes were measured by comparing the Hamilton 
Classification scores of each participant at the beginning of the trial to their score at the end of 
the 24 months.   The subjective therapeutic effectiveness for both therapies was also evaluated by 
three dermatologists, however these outcomes are not reviewed in this paper.3  
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The studies above were found using PubMed.  The keywords used for PubMed were 
finasteride and alopecia.   Articles that evaluated outcomes that measured patient oriented 
evidence that matters (POEM’s) from 2007-2017 were selected. The population studied was men 
ages 18 and older that have androgenetic alopecia. Populations excluded were women, children 
under the age of 18, and those with hair loss due to etiologies other than androgenetic alopecia. 
The statistics reported in these articles were p-values (p<0.05 were considered clinically 
significant), number needed to treat, and mean change from baseline.  Table 1 shows the 
demographics and characteristics of the included studies. 
 
Outcomes Measured  
The patient oriented outcomes measured in these trials were patient satisfaction with the 
therapy at the end of the trial, mean change in size of alopecia, subjective overall effectiveness of 
therapy at the end of the trial, and overall change in rating of alopecia based on the Hamilton 
Classification Scale for androgenetic alopecia.   Gubelin Harcha et al. used the Hamilton-
Norwood Classification Scale to evaluate change in the participants’ baseline androgenetic 
alopecia to assess their response to therapy at the end of 24 weeks. They also used a 3-qusetion 
survey and a 5-question survey at the 12th and 24th week to assess to the participants’ perception 
of the therapeutic effectiveness of the randomly assigned medication they received.  Hajheydari 
et al. compared the size of the area of alopecia (cm) before and after the trial was conducted. 
Rossi et al. used the Hamilton Classification Scale to compare each participants’ stage of 
androgenetic alopecia from before the trial to their staging at the end of the trial.  The change in 
staging was used to assess the participant’s response to therapy.  
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Table 1: Demographics and Characteristics of included studies 
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions  
Gubelin1 Double 
Blind RCT 
917 Men  
20-50 
-Alopecia 
type III 
vertex, IV, V  
(based off 
Hamilton-
Norwood 
scale) 
 
-Maintain 
same hair 
color & style  
-serum 
testosterone less 
than 250 ng/dL 
-unstable liver 
disease 
-h/o malignancy 
within prior 5 yrs  
-prostate CA in 
1st degree  
-PSA > 2.0 
ng/ML 
-hair loss not 
caused by 
androgenetic 
alopecia 
-any 
condition/disease 
of scalp/hair 
156 PO finasteride 
1.0 mg/d  x 6 
months  
Hajheydari2 Double 
Blind RCT 
45 Men 
Under 
30 
-Males < 30 
with 
androgenetic 
alopecia 
Hair loss less 
than 5 yrs 
-max 
diameter of 
hair loss less 
than 10cm 
 
-Males with 
androgenetic 
alopecia who are 
under treated 
-males with 
baseline disease 
that causes hair 
loss  
7 PO finasteride 
1.0mg/d x 6 
months  
Rossi 3 Randomized 
open label 
study 
100 Men 
20-40 
Mild to 
moderate 
androgenetic 
alopecia 
based on 
Hamilton 
classification 
-Surgical 
alteration of scalp 
-topical minoxidil 
use in previous 
year 
-Men with 
alopecia as result 
of other causes 
 
0 PO finasteride 
1.0mg/d x 24 
months  
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Results  
 The double-blind randomized clinical trial conducted by Gubelin Harcha et al. included 
917 men between the ages 20-50 years old.  Of the 917 men participating, 761 completed the 
trial.  Twenty-one withdrew from the trial due to adverse events, 9 due to protocol deviation, 48 
participants were lost to follow up, 20 were released at investigator discretion, and 58 withdrew 
consent.   All of the participants were diagnosed with androgenetic alopecia and were classified 
as either type III vertex, IV, or V based of the Hamilton-Norwood Classification Scale.  
Participants were randomly assigned to either one of the four control groups (Placebo, 
dutasteride 0.02mg/day PO, dutasteride 0.1mg/day PO, dutasteride 0.5mg/day PO) or the 
experimental group (finasteride 1mg/day PO).  181 participants were randomly assigned to the 
placebo group, 185 participants were assigned to dutasteride 0.02mg/day PO, 188 were assigned 
Dutasteride 0.1mg/day PO, 184 were assigned dutasteride 0.5mg/day PO, and 179 were assigned 
finasteride 1mg/day PO.  This review focused on using the placebo as the control group with 
1mg oral finasteride as the experimental group.6 
 Using the Hamilton-Norwood Classification scale for androgenetic alopecia, participants 
were classified at the end of 24 weeks as either worsening in stage, unchanged stage, or 
improvement in stage.  To dichotomize the data found in Table IV of Gubelin Harcha et al., this 
review classified participants as either improved from baseline or unimproved from baseline at 
the end of 24 weeks. This data is found in Table IV of Gubelin Harcha et. al. Table 2 shows the 
control event rate (CER), experimental event rate (EER), relative benefit increase (RBI), 
absolute benefit increase (ABI), and the calculated numbers needed to treat (NNT).6    
 Gubelin Harcha et al. also used a 3 question HGI and a 5 question HGSS to assess 
participants satisfaction with the therapy they received.  At week 24, participants receiving 1mg 
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tablet of finasteride had a mean increase of 2.5 and participants receiving the placebo had a mean 
increase of 1.1 on the HGI score (P< .001), a finding that is statistically significant.  Participants 
receiving finasteride had a mean increase of 10.1 on the HGSS, while participants receiving the 
placebo had a mean increase in 9.1 on the HGSS (P = 0.084), which is statistically insignificant.6    
Table 2. Baseline Change in Hamilton-Norwood Classification in Gubelin Harcha et. al. 
CER EER RBI ABI NNT 
0.185 0.267 0.443 .082 13 
 
The double-blind randomized control study conducted by Hajheydari et al. included 45 
men between the ages of 18 and 35 years old clinically diagnosed with androgenetic alopecia.  
Of the 45 men, 7 participants were excluded from the trial.  Participants were randomly divided 
into two groups.  Group A received topical finasteride gel and a placebo tablet.  Group B 
received a placebo gel and an oral tablet of finasteride 1mg. Participants were instructed to take 
their assigned tablet once daily and apply their assigned topical gel twice daily.    
Hajheydari et al. measured the size of alopecia (cm2) of participants before and after the 6-month 
trial.  Before the trial, the average size of alopecia in participants taking oral finasteride 1mg 
daily was 7.55 cm with a standard deviation of 2.28cm.  At the end of the 6-month trial, the 
average size of alopecia was recorded as 7.18cm with a standard deviation of 2.17cm.  The p-
value was found to be 0.07, which is statistically insignificant. Table 3 shows the mean change 
from baseline in participants using oral finasteride and topical finasteride.5 
Table 3: Average Change in Size of Alopecia in Hajheydari et al.  
 Finasteride 
Tablet Baseline 
Finasteride gel 
baseline 
Finasteride tablet at 
24 months 
Finasteride gel at 
24 months  
Size of 
alopecia (cm) 
7.55 7.21 7.18 6.72 
Standard 
Deviation 
2.28 2.08 2.17 2.41 
p-value 0.07 0.08 
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Rossi et al. conducted a randomized open label study with 100 men diagnosed with 
androgenetic alopecia, all completing the trial.  The participants were equally separated into two 
groups and treated with oral finasteride 1mg/day or Serenoa repens 320 mg/day.   In Table IIIa 
of Ross et al. the results of the Hamilton Classification score to assess the hair growth of 
participants treated with oral finasteride at the end of 24 months.  Rossi et al. classified 
participants as worsened, stable, or improved based of their Hamilton Classification at the end of 
the 24-month trial is shown.*  This review dichotomized the data by classifying the participants 
as either improved or unimproved.  The unimproved category includes both the worsened and 
stable classifications by Rossi et. al.  Of the 50 participants treated with finasteride, 34 were 
categorized as improved, and 16 were categorized as worsened or stable.  A chi-square of 6.09 
and a p-value of 0.013 were reported for this data and show that the data is significantly 
significant.  Table 4 of this review shows the CER, EER, RBI, ABI, and NNT of the trial 
conducted by Rossi et al.3 
 
 
Table 4.  Therapeutic response of oral finasteride compared to Serenoa repens by Rossi et 
al. 
CER EER RBI ABI NNT 
0.38 0.68 0.79 .30 4 
 
Discussion 
 Finasteride is a 5-alpha reductase inhibitor that was approved in 1997 by the FDA to treat 
androgenetic alopecia4.  The two randomized control trials and the one randomized open label 
study discussed in this paper examined the therapeutic advantage of oral finasteride in reversing 
hair loss in adult men diagnosed with androgenetic alopecia.  
                                                               Anderson, Finasteride for Androgenetic Alopecia 
	  
9	  
When compared to a placebo in Gubelin Harcha et al., oral finasteride was found to have 
a NNT of 13, which represents a large treatment effect.  A NNT of 13 means that for every 13 
patients treated with 1 mg/day of PO finasteride, one patient with androgenetic alopecia will 
experience an improvement of hair growth. Participants treated with finasteride showed a 
statistically significant subjective improvement in their amount of hair at the end of the 24-week 
trial. The p-value for the HGSS was greater than 0.05, indicating that participants treated with 
oral finasteride did not have significant improvement in satisfaction of therapy when compared 
to the placebo. One limitation of this study is the use of subjective questionnaires to assess 
therapeutic effectiveness of interventions, as participants may have different expectations of 
outcomes of therapy.  Other limitations of this study are only including men between the ages of 
20 to 50 years old, and the short duration of the trial.  
The study conducted by Hajheydari et al. showed finasteride did not have significant 
improvement in hair growth when compared to topical finasteride gel. Limitations of this study 
include the number participants, only including men under the age of 30, and excluding male 
with androgenetic alopecia for over 5 years.  
 Rossi et al. found a significant improvement in hair growth for participants taking oral 
finasteride when compared to Serenoa repens.  This study found a NNT of 4, meaning that for 
every 4 patients treated with finasteride, 1 will show improvement in hair growth in men with 
androgenetic alopecia.  Limitations of this study include using only men between the ages of 20 
and 40, using an open-label study, and comparing finasteride with a plant extract that is not FDA 
approved for the treatment of androgenetic alopecia in men.   
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Conclusion 
 
 The two randomized control trials and one randomized open label study examined in this 
review showed inconsistent data on whether or not 1mg of oral finasteride was effective in 
reversing hair loss in men with androgenetic alopecia.  Future studies should consider 
investigating the effect finasteride has on hair loss for a longer duration, on populations younger 
than 18 who have been diagnosed with androgenetic alopecia, effectiveness of different doses of 
PO finasteride, and the effect PO finasteride has on women suffering from androgenetic 
alopecia. This review studied the effectiveness of oral finasteride in reversing hair loss in men 
with androgenetic alopecia.
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